Literature DB >> 21562751

Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study.

Mieke Van Hemelrijck1, Göran Walldius, Ingmar Jungner, Niklas Hammar, Hans Garmo, Elisa Binda, Adrian Hayday, Mats Lambe, Lars Holmberg.   

Abstract

BACKGROUND: A detailed analysis of lipid profiles, using apolipoproteins, has not yet been conducted for prostate cancer (PCa). Since several etiological pathways have been proposed for PCa and lipids, we aimed to study this in a large Swedish cohort with 1,469 primary prostate cancers.
METHODS: A cohort (n = 69,735) of all men aged 35 years or older, whose levels of triglycerides (TG) (mmol/L), total cholesterol (mmol/L), glucose (mmol/L), LDL (mmol/L), HDL (mmol/L), apoB (g/L), and apoA-I (g/L) were measured at baseline, was selected from the Apolipoprotein MOrtality RISk (AMORIS) database. About 2,008 men developed PCa. Multivariate Cox proportional hazard models were used to analyze associations between lipid components and PCa.
RESULTS: ApoA-I and HDL were inversely associated with PCa risk (e.g., HR for HDL: 0.93 (95% CI: 0.81-1.07), 0.88 (0.76-1.01), 0.81 (0.70-0.94), for second, third, and fourth quartiles compared with the first quartile; with p for trend: 0.004; HR for apoA-I: 1.00 (0.88-1.13), 0.93 (0.82-1.05), 0.88 (0.77-0.99),), for second, third, and fourth quartiles compared with the first quartile; with p for trend: 0.022). ApoB, LDL, and non-HDL were not associated with PCa risk.
CONCLUSIONS: Our results show that low HDL and ApoA-I as well as increased lipid ratios are related to increased PCa risk. Experimental studies are required to tease out the underlying biological mechanisms linking these lipid components to PCa.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21562751     DOI: 10.1007/s10552-011-9774-z

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  30 in total

1.  Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study.

Authors:  Divya Seth; Hans Garmo; Annette Wigertz; Lars Holmberg; Niklas Hammar; Ingmar Jungner; Mats Lambe; Göran Walldius; Mieke Van Hemelrijck
Journal:  Int J Mol Epidemiol Genet       Date:  2012-05-15

2.  Uptake of high-density lipoprotein by scavenger receptor class B type 1 is associated with prostate cancer proliferation and tumor progression in mice.

Authors:  C Alicia Traughber; Emmanuel Opoku; Gregory Brubaker; Jennifer Major; Hanxu Lu; Shuhui Wang Lorkowski; Chase Neumann; Aimalie Hardaway; Yoon-Mi Chung; Kailash Gulshan; Nima Sharifi; J Mark Brown; Jonathan D Smith
Journal:  J Biol Chem       Date:  2020-05-01       Impact factor: 5.157

3.  Proteomic identification of alpha-2-HS-glycoprotein as a plasma biomarker of hypopharyngeal squamous cell carcinoma.

Authors:  Wen-Dong Tian; Jun-Zheng Li; Shui-Wang Hu; Xiao-Wei Peng; Gang Li; Xiong Liu; Huai-Hong Chen; Xia Xu; Xiang-Ping Li
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 4.  Cholesterol and prostate cancer.

Authors:  Kristine Pelton; Michael R Freeman; Keith R Solomon
Journal:  Curr Opin Pharmacol       Date:  2012-07-21       Impact factor: 5.547

5.  Serum total and HDL cholesterol and risk of prostate cancer.

Authors:  Alison M Mondul; Stephanie J Weinstein; Jarmo Virtamo; Demetrius Albanes
Journal:  Cancer Causes Control       Date:  2011-09-14       Impact factor: 2.506

6.  Shared common variants in prostate cancer and blood lipids.

Authors:  Ole A Andreassen; Verena Zuber; Wesley K Thompson; Andrew J Schork; Francesco Bettella; Srdjan Djurovic; Rahul S Desikan; Ian G Mills; Anders M Dale
Journal:  Int J Epidemiol       Date:  2014-04-30       Impact factor: 7.196

7.  Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model.

Authors:  Elizabeth M Masko; Mahmoud A Alfaqih; Keith R Solomon; William T Barry; Christopher B Newgard; Michael J Muehlbauer; Nikolaos A Valilis; Tameika E Phillips; Susan H Poulton; Alexis R Freedland; Stephanie Sun; Shweta K Dambal; Sergio E Sanders; Everardo Macias; Michael R Freeman; Mark W Dewhirst; Salvatore V Pizzo; Stephen J Freedland
Journal:  Prostate       Date:  2016-11-30       Impact factor: 4.104

8.  Serum differential protein identification of Xinjiang Kazakh esophageal cancer patients based on the two-dimensional liquid-phase chromatography and LTQ MS.

Authors:  Cui Li; Guo Xia; Zhang Jianqing; Yang Mei; Bai Ge; Zhang Li
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

9.  Anticancer activity of the cholesterol exporter ABCA1 gene.

Authors:  Bradley Smith; Hartmut Land
Journal:  Cell Rep       Date:  2012-09-13       Impact factor: 9.423

10.  Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk.

Authors:  Mathilde His; Laurent Zelek; Mélanie Deschasaux; Camille Pouchieu; Emmanuelle Kesse-Guyot; Serge Hercberg; Pilar Galan; Paule Latino-Martel; Jacques Blacher; Mathilde Touvier
Journal:  Eur J Epidemiol       Date:  2014-02-13       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.